Hospira

Hospira Competitive Intelligence & Landscape

hospira.com ·

Overview

Hospira Overview

Hospira (hospira.com) was a prominent global provider of injectable drugs and infusion technologies, as well as a significant player in biosimilars. The company's core business revolved around these pharmaceutical offerings, serving a worldwide market.

In 2015, Hospira, Inc. was acquired by Pfizer Inc. [https://pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-hospira]. Following this acquisition, Hospira's operations and expertise in injectable drugs and infusion technologies were integrated into Pfizer's portfolio, expanding Pfizer's capabilities and commitment to serving patients globally.

While information about specific founding year and headquarters for the original Hospira.com is now linked to Pfizer's acquisition, the company's impact as a leading pharmaceutical manufacturer, particularly in the sterile injectables and biosimilars sectors, was substantial prior to its integration into Pfizer.

Hospira

Hospira Weekly Intel Updates

Receive weekly intel updates about Hospira straight to your inbox.

Competitors

Hospira Competitors

Hospira (hospira.com) faces competition from several key players in the specialty injectable pharmaceuticals and medication management systems markets. One significant competitor is Fresenius Kabi, a division of Fresenius AG, which offers essential medicines and technologies across Pharma, Biopharma, Nutrition, and MedTech. Fresenius Kabi directly competes with Hospira in both injectable drugs and infusion technologies, often presenting similar product portfolios for hospital and alternate site care [https://rocketreach.co/hospira-profile_b5c498a8f42e0dc7].

Baxter International Inc. is another major competitor for Hospira, particularly in both specialty injectable pharmaceuticals and medication management systems [https://en.wikipedia.org/wiki/Hospira]. Baxter offers a broad range of products, including IV solutions, infusion systems, and injectable drugs, positioning itself as a comprehensive provider in hospital and clinical settings. Their long-standing presence and extensive product offerings make them a direct rival to Hospira in features, market share, and product breadth.

In the realm of generic medicines and biosimilars, Lek stands out as a direct competitor to Hospira [https://www.cbinsights.com/company/hospira/alternatives-competitors]. Lek specializes in developing, manufacturing, and marketing generic medicines and biosimilars, offering a broad portfolio of treatments. While detailed pricing and market share comparisons are not readily available, Lek's focus on these specific areas indicates a direct challenge to Hospira's core business in cost-effective pharmaceutical solutions.

Teva Pharmaceuticals is also a strong competitor in specialty injectable pharmaceuticals and generics. Teva is known for its extensive portfolio of generic drugs, including injectable formulations, and has a significant global market presence [https://en.wikipedia.org/wiki/Hospira]. Their competitive pricing strategies and broad product availability challenge Hospira's position in the generic injectable market, impacting market share for similar products.

Product & Pricing

Hospira Product and Pricing Intelligence

It is not possible to provide detailed product and pricing intelligence for Hospira based on the current information available through public web searches.

Hospira.com redirects to Pfizer.com, indicating that Hospira as an independent entity with its own products, pricing plans, and public-facing tiers no longer operates under that domain. Therefore, there are no current pricing plans, tiers, or details about free vs. paid features to describe for Hospira.com.

The acquisition of Hospira by Pfizer in 2015 means that any products previously offered by Hospira would now be integrated into Pfizer's portfolio. To understand the pricing and product details for these legacy Hospira offerings, one would need to consult Pfizer's official channels or product catalogs, which would not be under the Hospira.com domain.

Consequently, there are no recent pricing changes specific to Hospira.com to report, as the domain itself no longer hosts an active, independent business. Any changes related to the products originally developed by Hospira would be reflected within Pfizer's broader pricing strategies and public announcements.

Ad Campaigns

Hospira Ad Campaigns

See the live ads Hospira is running across Google, Meta, and LinkedIn — the creative, messaging, and platforms behind every campaign, updated automatically by ForesightIQ.

See of Hospira's ads

View ads

Hiring & Layoffs

Hospira Hiring and Layoffs

Information directly pertaining to the hiring and layoff trends of Hospira (hospira.com) is not available through the provided search results. While there is a mention of "Hospira" as a talent source for HOSPIRA ITALIA SRL [linkedin.com/company/hospira-italia-srl], this entity operates under the domain hospira.it and has a very small employee count, making it distinct from the target domain hospira.com. Therefore, it is not possible to determine recent hiring trends, notable job openings, or any layoffs for Hospira based on the given sources.

The search results primarily focus on general job platforms and recruiting services, such as Jobs in United States [linkedin.com/company/jobs-in-united-states-usa], PrimeChances [primechances.com], IdealTraits [idealtraits.com], Super Recruiter [superrecruiter.io], InformedJobs [informedjobs.com], Work for Good [workforgood.org], and Joe Produce [joeproduce.com]. These platforms offer services for job seekers and employers across various industries, but none specifically provide details about Hospira's hiring activities.

Without direct information about Hospira (hospira.com), it is not possible to analyze their hiring patterns or infer strategic shifts from such data. The available sources do not contain any job listings, employment figures, or news related to hiring or layoffs for the company at hospira.com.

Leadership

Hospira Management and Leadership Team

Information about Hospira's (hospira.com) management and leadership team is limited due to the company's acquisition by Pfizer in 2015. Prior to the acquisition, Hospira operated as an independent entity, and its leadership would have included a CEO, CFO, and other C-suite executives, along with a board of directors. However, after the acquisition, Hospira's leadership structure was integrated into Pfizer's, and its former executives likely transitioned to roles within Pfizer or departed the company.

During its time as an independent company, Hospira was known for its focus on injectable drugs and infusion technologies. The leadership team at that time would have been responsible for guiding its strategic direction, product development, and market presence. Specific names and detailed roles of pre-acquisition executives and board members are not readily available in public records concerning the current state of hospira.com, which redirects to Pfizer's website.

Since hospira.com now redirects to Pfizer's official website, any current leadership or management information directly associated with the "Hospira" brand would fall under Pfizer's corporate structure. Therefore, the current executives and board members that would oversee the former Hospira operations are those of Pfizer itself. This includes Pfizer's Chairman and CEO, Albert Bourla, and other members of Pfizer's executive leadership team and board of directors.

Financials

Hospira Financial Performance, Fundraising, M&A

Information regarding the financial performance, fundraising, and M&A activities specifically for Hospira at hospira.com is not available from the provided search results. The available information primarily pertains to entities with similar names but different domains or business focuses.

For instance, "Hospira Inc" is listed as an Information Technology & Services company headquartered in Clayton, United States, employing 8 people [https://linkedin.com/company/hospira-inc]. "HOSPIRA ITALIA SRL" is identified as a Pharmaceutical Manufacturing company in Italy with 4 employees, and its homepage is hospira.it, not hospira.com [https://linkedin.com/company/hospira-italia-srl].

Additionally, "HOSPIRA HEALTHCARE INDIA PRIVATE LIMITED" is described as a Mining company [https://linkedin.com/company/hospira-healthcare-india-private-limited], and various "Zydus Hospira Oncology Private Ltd" entities are in Medical Equipment Manufacturing and joint ventures [https://linkedin.com/company/zydus-hospira-oncology-private-ltd.], [https://linkedin.com/company/zydus-hospira-oncology-private-ltd-joint-venture]. These do not directly provide financial performance data for Hospira (hospira.com).

Partnerships

Hospira Partnerships, Clients and Vendors

While researching Hospira (hospira.com) for its partnerships, clients, and vendors, it's important to note that the company's online presence and current operations are limited. Publicly available information directly from hospira.com regarding its active partnerships, key enterprise clients, technology integrations, or current vendor relationships is not readily accessible.

Historically, Hospira was a major player in the pharmaceutical and medical device industries, known for its sterile injectable pharmaceuticals, infusion technologies, and biosimilars. During its active period, it would have engaged in numerous collaborations with healthcare providers, other pharmaceutical companies, and technology providers for drug development, distribution, and hospital solutions.

However, Hospira was acquired by Pfizer in 2015. Following this acquisition, many of its operations, products, and former partnerships were integrated into Pfizer's larger structure. Therefore, information about its historical client base and vendor ecosystem would largely reside within Pfizer's archives or be associated with specific product lines that continue under the Pfizer brand.

Events

Hospira Event Participations

I cannot provide information about Hospira's (hospira.com) event participations because hospira.com redirects to pfizer.com

Therefore, there is no distinct company website for Hospira at hospira.com to research regarding past or upcoming events. Any information found would pertain to Pfizer or be historical in nature before the redirect occurred.

Without a dedicated Hospira website at hospira.com, it is impossible to accurately detail their specific event sponsorships, attendance, or hosting activities.

Frequently Asked Questions

What is the current operational status of Hospira (hospira.com)?

Hospira (hospira.com) currently redirects to Pfizer.com, indicating it no longer operates as an independent entity with its own distinct website or public-facing operations. The company was acquired by Pfizer Inc. in 2015, and its former operations and product lines have since been integrated into Pfizer's portfolio.

What was Hospira's primary business focus before its acquisition?

Before its acquisition by Pfizer in 2015, Hospira was a leading global provider of injectable drugs and infusion technologies, and a significant player in the biosimilars market. Its core business served a worldwide market with these pharmaceutical offerings.

Who acquired Hospira and when?

Hospira, Inc. was acquired by Pfizer Inc. in 2015. Following the acquisition, Hospira's expertise in injectable drugs and infusion technologies became part of Pfizer's portfolio.

Which companies were considered key competitors for Hospira in the injectable pharmaceuticals market?

Hospira faced significant competition from companies like Fresenius Kabi and Baxter International Inc. in the injectable pharmaceuticals and medication management systems markets. Lek and Teva Pharmaceuticals were also key competitors, particularly in generic medicines and biosimilars.

What alternatives existed for customers seeking infusion technologies provided by Hospira?

For customers seeking infusion technologies similar to Hospira's, alternatives included KORU Medical Systems, which focused on home-based infusion systems, and Akas Infusions, specializing in critical care infusion pumps with a global reach. Assure Infusions also offered specialized sterile IV bag manufacturing for hospitals.

Can current financial performance or M&A activities for Hospira (hospira.com) be determined?

No, current financial performance, fundraising, or M&A activities specifically for Hospira (hospira.com) cannot be determined from available information. The original Hospira Inc. was acquired by Pfizer in 2015, and its financials are now integrated into Pfizer's reporting. Other entities with 'Hospira' in their name operate under different domains and business focuses.

Is there information available on Hospira's current leadership team?

Information about Hospira's current leadership team is not available as a distinct entity. Following its 2015 acquisition by Pfizer, Hospira's leadership structure was integrated into Pfizer's. Any oversight of former Hospira operations now falls under Pfizer's executive leadership team and board of directors.

What does the redirect of hospira.com to pfizer.com imply about Hospira's product offerings and pricing?

The redirect implies that Hospira no longer operates as an independent entity with its own public product catalog or pricing plans. Any products previously offered by Hospira are now integrated into Pfizer's portfolio, and their current pricing and details would be found through Pfizer's official channels.

Does Hospira (hospira.com) have any active partnerships or client relationships that can be identified?

No, publicly available information directly from hospira.com regarding active partnerships, key enterprise clients, or current vendor relationships is not accessible. After the 2015 acquisition by Pfizer, many of Hospira's operations and former partnerships were integrated into Pfizer's larger structure.

Are there any recent hiring or layoff trends identifiable for Hospira (hospira.com)?

No recent hiring or layoff trends for Hospira (hospira.com) can be identified. The domain redirects to Pfizer.com, and specific employment data for Hospira as an independent entity is not available. Other entities with similar names, such as HOSPIRA ITALIA SRL, are distinct and have very small employee counts.

What role did Lek play as an alternative to Hospira?

Lek was an alternative to Hospira, specializing in developing, manufacturing, and marketing generic medicines and biosimilars. Both companies offered a broad portfolio of treatments, but Lek's specific emphasis on generics and biosimilars provided a distinct option for segments of the healthcare market prioritizing cost-effectiveness.

Powered by ForesightIQ · Competitive intelligence from digital exhaust